Clinical Trial Update: PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating PAM50 HER2-enriched phenotype as a predictor of response to dual HER2 blockade in HER2-positive early breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED